This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
Ichnos will receive an upfront payment of Euro 20.8 million as well as additional development and commercial milestone payments and tiered royalties based upon future global sales
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
India business grew 11.8% YoY vs mid-single digit industry growth.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)